Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors

Histopathology. 2022 Nov;81(5):670-679. doi: 10.1111/his.14772. Epub 2022 Sep 5.

Abstract

Secretory carcinoma (SC) is a rare form of salivary carcinoma that was first described in 2010 and is characterized by ETV6::NTRK3 fusion in most cases. In this large retrospective study, we aimed to identify adverse clinicopathologic factors and propose a prognostically relevant grading scheme for SC.

Methods: A detailed clinicopathologic review was conducted on 90 SCs from the major and minor salivary glands.

Results: The median age at presentation was 50 years (range: 7-93). Sixty-nine (77%) tumours originated from major salivary glands, whereas the remaining 21 involved minor salivary glands.Six cases (7%) had cervical nodal metastasis. Only lymphovascular invasion (LVI) was associated with a risk of nodal metastasis (P < 0.05). The 5-year disease-specific survival and disease-free survival (DFS) were 98% and 87%, respectively. On univariate survival analysis, adverse prognostic factors associated with decreased DFS included minor salivary gland origin, atypical mitosis, high mitotic index, high-grade transformation (HGT), necrosis, nuclear pleomorphism, infiltrative tumour border, fibrosis at the invasive front, LVI, positive margin, and advanced pT stage (P < 0.05). When adjusted for pT stage and margin status, mitotic index, LVI, nuclear pleomorphism, and HGT remained as independent prognostic factors.

Conclusion: We therefore propose a two-tiered grading system for SC. The low-grade SC is defined as those with <5 mitoses /10 high-power fields and no tumour necrosis, and high-grade SC as those with ≥5 mitoses /10 high-power fields and/or necrosis. This proposed grading system can be useful to risk stratify patients with SC for appropriate clinical management.

Keywords: ETV6::NTRK3 fusion; Secretory carcinoma; grading; prognosis; salivary gland carcinoma.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms
  • Carcinoma* / pathology
  • Child
  • Humans
  • Middle Aged
  • Necrosis
  • Oncogene Proteins, Fusion
  • Prognosis
  • Retrospective Studies
  • Salivary Gland Neoplasms* / pathology
  • Salivary Glands / pathology
  • Young Adult

Substances

  • Oncogene Proteins, Fusion

Supplementary concepts

  • Secretory breast carcinoma